Amgen Ducks Supreme Court Review of Patents on Enbrel Drug

Amgen Ducks Supreme Court Review of Patents on Enbrel Drug

The Supreme Court turned away a petition that sought to challenge two Amgen Inc. patents on the top-selling rheumatoid arthritis drug Enbrel, ensuring Novartis AG’s Sandoz won’t be able to sell a biosimilar of the drug in the U.S. until 2029.

Read More…

You May Also Like